ArticleJournal of medicinal chemistry2026
A Potent and Selective Quinolone-Based PTPN22 Inhibitor with Improved Immunotherapeutic Activity.
Jianping Lin, Brenson A Jassim, Yunpeng Bai, Zihan Qu, Frederick Nguele Meke, Jiajun Dong, Li Wu, Benjamin Babalola, Jingmei Yu, Haoran Zhang and 1 more
Abstract read
In one paragraphArticle in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Jianping LinBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana 47907, United States.
Brenson A JassimBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana 47907, United States.
Yunpeng BaiBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana 47907, United States.
Zihan QuThe James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States.
Frederick Nguele MekeBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana 47907, United States.
Jiajun DongBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana 47907, United States.
Li WuInstitute for Drug Discovery, Purdue University, West Lafayette, Indiana 47907, United States.
Benjamin BabalolaThe James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0000-0001-8188-9056 Jingmei YuBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0009-0001-1826-6902 Haoran ZhangBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana 47907, United States.
Zhong-Yin ZhangBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0000-0001-5527-7910 Funding
Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI ANDREW D MESECAR · 1985 to 2026
$43.4MStructure/Function of Protein Tyrosine PhosphatasesR01CA069202 · NCI · YESHIVA UNIVERSITY · PI Zhong-Yin Zhang · 1996 to 2026
$7.3MNCI NIH HHS P30 CA023168NCI NIH HHS R01 CA069202
6 · The paper itselfAbstract
Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) is a cytosolic enzyme expressed primarily in hematopoietic cells that negatively regulates T cell signaling and antitumor immune response. Genetic and pharmacological studies have demonstrated that PTPN22 is a systemic immunotherapy target that can enhance T cell activation and function when abrogated, resulting in reduced tumor burden. Building on our previously reported PTPN22 inhibitor,
Indexed as
Antineoplastic AgentsEnzyme InhibitorsImmunotherapyProtein Tyrosine Phosphatase, Non-Receptor Type 22QuinolonesAnimalsCell Line, TumorHumansMiceStructure-Activity RelationshipAntineoplastic AgentsEnzyme InhibitorsProtein Tyrosine Phosphatase, Non-Receptor Type 22PTPN22 protein, humanQuinolones
Identifiers
PMID42388138
PMCPMC13403317
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390